Nu Skin Unfazed By Allegations Of China Violations, Projects More Growth
This article was originally published in The Tan Sheet
Following allegations from short seller Citron Research that it operates a “pyramid compensation scheme” in China, Nu Skin gives investors a peek into its business model. The firm recorded sales growth of 40% in its second quarter, driven by a 152% jump in China, and “the best is yet to come,” Nu Skin says.
You may also be interested in...
Sanofi’s Allegra down from year-ago launch as stocking declines; competitive China landscape weighs on Mead Johnson; GNC revenue up double digits across segments; Claritin shows life in Merck consumer unit; USANA reports return to Western growth; Nu Skin preps ageLOC weight management launch.
Nu Skin Enterprises acquires LifeGen Technologies for $11.7 million to ensure that the direct seller’s anti-aging business continues to benefit from LifeGen’s research into the genetic basis for aging.
Increased scrutiny of anti-aging products with sunscreen ingredients entering the U.S. presages "a major enforcement initiative" against personal care product firms making noncompliant claims, according to a food and drug attorney who worked at FDA on import enforcement